Skip to main content
. 2012 Jul 9;590(Pt 21):5273–5297. doi: 10.1113/jphysiol.2012.236893

Figure 7. Effects of bumetanide on forskolin-stimulated Ieq and fluid secretion.

Figure 7

A, basolateral pretreatment with the NKCC1 inhibitor bumetanide (20 μmol l−1) partially inhibited basal Ieq (∼20%) but did not prevent forskolin-stimulated Ieq or HCO3− secretion (n= 6). B, basolateral bumetanide (20 μmol l−1) inhibited ∼20% of the Ieq (•) without affecting HCO3− secretion (º) (n= 6). C, forskolin-stimulated fluid secretion was inhibited ∼15% by bumetanide (▴) when compared with forskolin alone (▪) (n= 6 each condition; means ± SEM).